🇺🇸 ombitasvir/paritaprevir/ritonavir, dasabuvir in United States

25 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 25

Most-reported reactions

1. Nausea — 4 reports (16%)
2. Ascites — 3 reports (12%)
3. Hepatic Failure — 3 reports (12%)
4. Vomiting — 3 reports (12%)
5. Anaemia — 2 reports (8%)
6. Asthenia — 2 reports (8%)
7. Cardiac Failure — 2 reports (8%)
8. Encephalopathy — 2 reports (8%)
9. Hyperbilirubinaemia — 2 reports (8%)
10. Malaise — 2 reports (8%)

Source database →

Frequently asked questions

Is ombitasvir/paritaprevir/ritonavir, dasabuvir approved in United States?

ombitasvir/paritaprevir/ritonavir, dasabuvir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ombitasvir/paritaprevir/ritonavir, dasabuvir in United States?

AbbVie is the originator. The local marketing authorisation holder may differ — check the official source linked above.